{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:15:10Z","timestamp":1787166910688,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.gastrohep.2021.11.012","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:29:40Z","timestamp":1639654180000},"page":"561-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Budesonide in the first line treatment of patients with autoimmune hepatitis"],"prefix":"10.1016","volume":"45","author":[{"given":"Ignasi","family":"Olivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Cobreros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-1586","authenticated-orcid":false,"given":"Mar\u00eda-Carlota","family":"Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-2263","authenticated-orcid":false,"given":"\u00c1lvaro","family":"D\u00edaz-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2021.11.012_bib0175","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"Lohse","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0180","article-title":"Autoimmune hepatitis","volume":"4","author":"Mieli-Vergani","year":"2018","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0185","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0190","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jhep.2020.12.033","article-title":"Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score","volume":"74","author":"De Martin","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0195","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams","year":"2018","journal-title":"Respir Care"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0205","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/cr.2014.52","article-title":"Structures and mechanism for the design of highly potent glucocorticoids","volume":"24","author":"He","year":"2014","journal-title":"Cell Res"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0210","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2036.1997.tb00814.x","article-title":"Review article: drug development in inflammatory bowel disease: budesonide \u2013 a model of targeted therapy","volume":"11","author":"Hamedani","year":"1997","journal-title":"Aliment Pharmacol Ther Suppl"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/164_2016_98","article-title":"Glucocorticoids","volume":"237","author":"Adcock","year":"2016","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0220","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(77)90233-9","article-title":"Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary\u2013adrenal function","volume":"63","author":"Meikle","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0225","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn's disease","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0230","first-page":"1","article-title":"Budesonide","author":"Kalola","year":"2021","journal-title":"xPharm Compr Pharmacol Ref"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0235","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1155\/1990\/708916","article-title":"Overview of newer glucocorticosteroid preparations for inflammatory bowel disease","volume":"4","author":"Brattsand","year":"1990","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0240","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0245","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3748\/wjg.v9.i12.2681","article-title":"Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC","volume":"9","author":"Geier","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0250","unstructured":"Ficha T\u00e9cnica Budesonida 3 MG. Agencia Espa\u00f1ola Medicam y Prod Sanit; 2019."},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0255","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2036.1994.tb00334.x","article-title":"Oral budesonide for treatment of autoimmune chronic active hepatitis","volume":"8","author":"Danielsson","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0260","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1478-3231.2005.01122.x","article-title":"Budesonide in previously untreated autoimmune hepatitis","volume":"25","author":"Wiegand","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0265","first-page":"163","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","author":"Woynarowski","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0270","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/1751-2980.12085","article-title":"Autoimmune hepatitis in southern Israel: a 15-year multicenter study","volume":"14","author":"Delgado","year":"2013","journal-title":"J Dig Dis"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0275","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3325\/cmj.2019.60.345","article-title":"The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis: a retrospective study","volume":"60","author":"Binicier \u00d6B","year":"2019","journal-title":"Croat Med J"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0280","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/apt.15528","article-title":"Adverse events related to low dose corticosteroids in autoimmune hepatitis","volume":"50","author":"van den Brand","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0285","first-page":"951","volume":"48","author":"Dyson","year":"2018","journal-title":"Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0290","article-title":"Eficacia y seguridad de la budesonida como primera l\u00ednea de tratamiento en pacientes con hepatitis autoinmune: Estudio multic\u00e9ntrico espa\u00f1ol","author":"\u00c1. D\u00edaz-Gonz\u00e1lez","year":"2021","journal-title":"Congr Anu Asoc Espa\u00f1ola para el Estud del H\u00edgado"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0295","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.autrev.2011.09.006","article-title":"Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome","volume":"11","author":"Efe","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0300","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0305","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1159\/000492204","article-title":"Secondary adrenal insufficiency after treatment with budesonide for autoimmune hepatitis","volume":"12","author":"De Maeyer","year":"2018","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0310","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.crohns.2012.06.006","article-title":"Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study","volume":"7","author":"Suzuki","year":"2013","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0315","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","article-title":"Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial","volume":"21","author":"Hanauer","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gutjnl-2014-308363","article-title":"Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial","volume":"65","author":"M\u00fcnch","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0325","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/jgh.14151","article-title":"Oral budesonide in gastrointestinal and liver disease: a practical guide for the clinician","volume":"33","author":"Miehlke","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0330","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.gastrohep.2018.05.013","article-title":"Reviewing the therapeutic role of budesonide in Crohn's disease","volume":"41","author":"L\u00f3pez-Sanrom\u00e1n","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0335","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0340","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1572-0241.2002.05609.x","article-title":"Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy","volume":"97","author":"Cino","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0345","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0350","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"301","author":"Murray-Lyon","year":"1973","journal-title":"Lancet."},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0355","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","article-title":"Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared","volume":"16","author":"Summerskill","year":"1975","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0360","first-page":"95","article-title":"Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD)","volume":"2","author":"Tage-Jensen","year":"1982","journal-title":"Relation to a serological classification. Liver."},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0365","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","article-title":"Treatment options for autoimmune hepatitis: A systematic review of randomized controlled trials","volume":"53","author":"Lamers","year":"2010","journal-title":"J Hepatol."},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0370","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3748\/wjg.v12.i9.1362","article-title":"Budesonide induces complete remission in autoimmune hepatitis","volume":"12","author":"Csepregi","year":"2006","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0375","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0380","first-page":"1","article-title":"Hellenic association for the study of the liver clinical practice guidelines: Autoimmune hepatitis","volume":"32","author":"Dalekos","year":"2019","journal-title":"Ann Gastroenterol."},{"key":"10.1016\/j.gastrohep.2021.11.012_bib0385","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/gut.2010.235259","article-title":"British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis","volume":"60","author":"Gleeson","year":"2011","journal-title":"Gut."}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570521003198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570521003198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:45:50Z","timestamp":1759322750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570521003198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0210570521003198"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2021.11.012","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budesonide in the first line treatment of patients with autoimmune hepatitis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2021.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}